Cover image not available

Costing statement : Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carci

National Institute for Health and Clinical Excellence

Publication Data

Title Costing statement : Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carci
Alternative Title Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 0000
Publication location London

Topics

England

Catalogue Data

OBNB ID GBB586049
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99461061

ISBD

P1053 1 online resource (3 pages)
P1042 Includes bibliographical references.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Costing statement : Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carci by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence. Publication and catalogue information, links to buy online and reader comments.